PROGRESSIVE MULTIFOCAL LEUCOENCEPHALOPATHY

Progressive Multifocal Leukoencephalopathy: Recent Advances and a Neuro-Ophthalmological Review

BACKGROUND

Progressive multifocal leukoencephalopathy (PML) is a severe often fatal opportunistic infection of the central nervous system caused by reactivation of a ubiquitous polyoma virus, JC virus. Although typically characterized by multifocal asymmetric subcortical white matter lesions, it may be monofocal and affect the cortical gray matter. Among the broad spectrum of clinical manifestations that occurs with PML, visual complaints are common.

EVIDENCE ACQUISITION

Combination of representative personally observed cases of PML and comprehensive review of case series of PML from 1958 through 2014.

RESULTS

Neuro-ophthalmic signs and symptoms were reported in approximately 20%-50% of patients with PML and can be the presenting manifestation in half of these. A majority of these presentations occur from damage to cerebral visual pathways resulting in visual field defects, cortical blindness, and other disorders of visual association. Given the decreased frequency of infratentorial and cerebellar involvement, ocular motility disorders are less common.

CONCLUSIONS

Visual complaints occur in patients with PML and are often the presenting sign. Awareness of this condition is helpful in avoiding unnecessary delays in the diagnosis of PML and management of the underlying condition. Recent guidelines have established criteria for diagnosis of PML in the high-risk patient population and strategies to mitigate the risk in these populations.

Drug-induced PML: a global agenda for a global challenge

The occurrence of severe adverse events such as progressive multifocal leukoencephalopathy (PML) has the potential to limit the benefits of highly efficacious medicines being developed to fulfill unmet clinical needs across therapeutic areas. Following an Expert meeting in London in July 2011 (http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/09/WC500111562.pdf), a research agenda, highlighting methodological, clinical, and communication elements, to mitigate the risk and improve the management of drug-induced PML has been agreed upon.

Progressive multifocal leukoencephalopathy showing extensive spinal cord involvement in a patient with lymphocytopenia

A 64-year-old Japanese man who was diagnosed as having cerebral infarcts at an early clinical stage was found to have progressive multifocal leukoencephalopathy (PML). A decrease of leukocytes and lymphocytes had been detected in the previous year. During a total clinical course of 11 months, he showed marked depletion of lymphocytes ranging from 264/microL to 459/microL. Autopsy disclosed no underlying diseases such as malignancies or tuberculosis. Extensive PML lesions were seen in the cerebral white matter. Small perivascular cuffs comprising many CD8+ T lymphocytes and a few CD4+ T cells were scattered in the PML lesions. CD20+ B cells were rarely evident. The subsets of the infiltrating lymphocytes differed from those of primary or spontaneous PML. Similar extensive PML lesions were observed not only in the cerebellum and brainstem but also in the spinal cord. All 26 segments of the spinal cord, especially the cervical, lumbar and sacral cord, showed extensive lesions involving the lateral and anterior columns. To our knowledge, only three cases of PML with such extensive spinal cord lesions have been reported previously. These three cases, and the present one, may represent a group of PML that shows extensive lesions in the spinal cord as well as the cerebrum, cerebellum and brainstem. The underlying disease in the present case was unclear. Because lymphocytopenia is not observed in primary or spontaneous PML, and the immunohistochemical findings of the infiltrating lymphocytes in the present case are different from primary or spontaneous PML, the decrease in his total blood lymphocytes may have played a significant role in his immunosuppressed condition as the underlying disease.

Polyomavirus models of brain infection and the pathogenesis of multiple sclerosis

Multiple sclerosis (MS) is generally considered to be an autoimmune disorder with myelin as the target and with several unidentified viruses playing ancillary roles, possibly through molecular mimicry. Although this paradigm has led to important progress on potential mechanisms of myelin loss, neither a target antigen in myelin nor a triggering mechanism has yet been identified, leaving the etiology of MS still unknown. Animal models of viral demyelination and studies showing that JC virus (JCV), the polyomavirus which causes progressive multifocal leukoencephalopathy (PML), may be latent in some normal human brains suggest another possibility. A host immune response targeting proteins expressed at low levels from viral DNA latent in the central nervous system (CNS) might underlie a focal demyelinating disease such as MS. A shift from autoimmunity to a latent-virus model is not a trivial substitution of target antigens. This shift would expand the search for a definitive laboratory test for MS and could lead to improved therapeutic and preventive approaches.